Pencil Banner Copy AUGUST2023

Elevar Therapeutics and Jiangsu Hengrui Pharma announce global commercialization licensing agreement for camrelizumab LEARN MORE HERE
Title Image

Investors

INVESTORS

NEW VIRTUAL KOL EVENT

Discussion on Phase 3 Study of Rivoceranib in Combination With
Camrelizumab in Unresectable Hepatocellular Carcinoma (uHCC)

ELEVAR CORPORATE PRESENTATION

Sign Up To Receive Investor Notifications

Elevar Press Releases Elevar Events Contact Elevar

Stay Informed on Elevar – follow us on Twitter and LinkedIn.